Copyright Reports & Markets. All rights reserved.

Global Hyperimmune Serum Market Research Report 2021

Request for Sample of this report
Buy now

1 Hyperimmune Serum Market Overview

  • 1.1 Product Overview and Scope of Hyperimmune Serum
  • 1.2 Hyperimmune Serum Segment by Type
    • 1.2.1 Global Hyperimmune Serum Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Hepatitis B Immunoglobulins
    • 1.2.3 Rabies Immunoglobulins
    • 1.2.4 Tetanus Immunoglobulins
    • 1.2.5 Rho(D) Immunoglobulins
    • 1.2.6 Other
  • 1.3 Hyperimmune Serum Segment by Application
    • 1.3.1 Global Hyperimmune Serum Sales Comparison by Application: (2021-2027)
    • 1.3.2 Government Institutions
    • 1.3.3 Private Sector
    • 1.3.4 Other
  • 1.4 Global Hyperimmune Serum Market Size Estimates and Forecasts
    • 1.4.1 Global Hyperimmune Serum Revenue 2016-2027
    • 1.4.2 Global Hyperimmune Serum Sales 2016-2027
    • 1.4.3 Hyperimmune Serum Market Size by Region: 2016 Versus 2021 Versus 2027

2 Hyperimmune Serum Market Competition by Manufacturers

  • 2.1 Global Hyperimmune Serum Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Hyperimmune Serum Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Hyperimmune Serum Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Hyperimmune Serum Manufacturing Sites, Area Served, Product Type
  • 2.5 Hyperimmune Serum Market Competitive Situation and Trends
    • 2.5.1 Hyperimmune Serum Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Hyperimmune Serum Players Market Share by Revenue
    • 2.5.3 Global Hyperimmune Serum Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Hyperimmune Serum Retrospective Market Scenario by Region

  • 3.1 Global Hyperimmune Serum Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.2 Global Hyperimmune Serum Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.3 North America Hyperimmune Serum Market Facts & Figures by Country
    • 3.3.1 North America Hyperimmune Serum Sales by Country
    • 3.3.2 North America Hyperimmune Serum Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Hyperimmune Serum Market Facts & Figures by Country
    • 3.4.1 Europe Hyperimmune Serum Sales by Country
    • 3.4.2 Europe Hyperimmune Serum Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Hyperimmune Serum Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Hyperimmune Serum Sales by Region
    • 3.5.2 Asia Pacific Hyperimmune Serum Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Hyperimmune Serum Market Facts & Figures by Country
    • 3.6.1 Latin America Hyperimmune Serum Sales by Country
    • 3.6.2 Latin America Hyperimmune Serum Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Hyperimmune Serum Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Hyperimmune Serum Sales by Country
    • 3.7.2 Middle East and Africa Hyperimmune Serum Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Hyperimmune Serum Historic Market Analysis by Type

  • 4.1 Global Hyperimmune Serum Sales Market Share by Type (2016-2021)
  • 4.2 Global Hyperimmune Serum Revenue Market Share by Type (2016-2021)
  • 4.3 Global Hyperimmune Serum Price by Type (2016-2021)

5 Global Hyperimmune Serum Historic Market Analysis by Application

  • 5.1 Global Hyperimmune Serum Sales Market Share by Application (2016-2021)
  • 5.2 Global Hyperimmune Serum Revenue Market Share by Application (2016-2021)
  • 5.3 Global Hyperimmune Serum Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 CSL Behring
    • 6.1.1 CSL Behring Corporation Information
    • 6.1.2 CSL Behring Description and Business Overview
    • 6.1.3 CSL Behring Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 CSL Behring Hyperimmune Serum Product Portfolio
    • 6.1.5 CSL Behring Recent Developments/Updates
  • 6.2 Grifols
    • 6.2.1 Grifols Corporation Information
    • 6.2.2 Grifols Description and Business Overview
    • 6.2.3 Grifols Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Grifols Hyperimmune Serum Product Portfolio
    • 6.2.5 Grifols Recent Developments/Updates
  • 6.3 Biotest
    • 6.3.1 Biotest Corporation Information
    • 6.3.2 Biotest Description and Business Overview
    • 6.3.3 Biotest Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Biotest Hyperimmune Serum Product Portfolio
    • 6.3.5 Biotest Recent Developments/Updates
  • 6.4 Kedrion
    • 6.4.1 Kedrion Corporation Information
    • 6.4.2 Kedrion Description and Business Overview
    • 6.4.3 Kedrion Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Kedrion Hyperimmune Serum Product Portfolio
    • 6.4.5 Kedrion Recent Developments/Updates
  • 6.5 CBPO
    • 6.5.1 CBPO Corporation Information
    • 6.5.2 CBPO Description and Business Overview
    • 6.5.3 CBPO Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 CBPO Hyperimmune Serum Product Portfolio
    • 6.5.5 CBPO Recent Developments/Updates
  • 6.6 Emergent (Cangene)
    • 6.6.1 Emergent (Cangene) Corporation Information
    • 6.6.2 Emergent (Cangene) Description and Business Overview
    • 6.6.3 Emergent (Cangene) Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Emergent (Cangene) Hyperimmune Serum Product Portfolio
    • 6.6.5 Emergent (Cangene) Recent Developments/Updates
  • 6.7 Kamada
    • 6.6.1 Kamada Corporation Information
    • 6.6.2 Kamada Description and Business Overview
    • 6.6.3 Kamada Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Kamada Hyperimmune Serum Product Portfolio
    • 6.7.5 Kamada Recent Developments/Updates
  • 6.8 CNBG
    • 6.8.1 CNBG Corporation Information
    • 6.8.2 CNBG Description and Business Overview
    • 6.8.3 CNBG Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 CNBG Hyperimmune Serum Product Portfolio
    • 6.8.5 CNBG Recent Developments/Updates
  • 6.9 Hualan Bio
    • 6.9.1 Hualan Bio Corporation Information
    • 6.9.2 Hualan Bio Description and Business Overview
    • 6.9.3 Hualan Bio Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Hualan Bio Hyperimmune Serum Product Portfolio
    • 6.9.5 Hualan Bio Recent Developments/Updates
  • 6.10 Shanghai RAAS
    • 6.10.1 Shanghai RAAS Corporation Information
    • 6.10.2 Shanghai RAAS Description and Business Overview
    • 6.10.3 Shanghai RAAS Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Shanghai RAAS Hyperimmune Serum Product Portfolio
    • 6.10.5 Shanghai RAAS Recent Developments/Updates
  • 6.11 Sichuan Yuanda Shuyang
    • 6.11.1 Sichuan Yuanda Shuyang Corporation Information
    • 6.11.2 Sichuan Yuanda Shuyang Hyperimmune Serum Description and Business Overview
    • 6.11.3 Sichuan Yuanda Shuyang Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Sichuan Yuanda Shuyang Hyperimmune Serum Product Portfolio
    • 6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
  • 6.12 ADMA Biologics
    • 6.12.1 ADMA Biologics Corporation Information
    • 6.12.2 ADMA Biologics Hyperimmune Serum Description and Business Overview
    • 6.12.3 ADMA Biologics Hyperimmune Serum Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 ADMA Biologics Hyperimmune Serum Product Portfolio
    • 6.12.5 ADMA Biologics Recent Developments/Updates

7 Hyperimmune Serum Manufacturing Cost Analysis

  • 7.1 Hyperimmune Serum Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Hyperimmune Serum
  • 7.4 Hyperimmune Serum Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Hyperimmune Serum Distributors List
  • 8.3 Hyperimmune Serum Customers

9 Hyperimmune Serum Market Dynamics

  • 9.1 Hyperimmune Serum Industry Trends
  • 9.2 Hyperimmune Serum Growth Drivers
  • 9.3 Hyperimmune Serum Market Challenges
  • 9.4 Hyperimmune Serum Market Restraints

10 Global Market Forecast

  • 10.1 Hyperimmune Serum Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Hyperimmune Serum by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Hyperimmune Serum by Type (2022-2027)
  • 10.2 Hyperimmune Serum Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Hyperimmune Serum by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Hyperimmune Serum by Application (2022-2027)
  • 10.3 Hyperimmune Serum Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Hyperimmune Serum by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Hyperimmune Serum by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Hepatitis B Immunoglobulins
    Rabies Immunoglobulins
    Tetanus Immunoglobulins
    Rho(D) Immunoglobulins
    Other

    Segment by Application
    Government Institutions
    Private Sector
    Other

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    CSL Behring
    Grifols
    Biotest
    Kedrion
    CBPO
    Emergent (Cangene)
    Kamada
    CNBG
    Hualan Bio
    Shanghai RAAS
    Sichuan Yuanda Shuyang
    ADMA Biologics

    Buy now